2-溴-1-(4-戊苯基)乙酮 | 64328-68-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-(4-戊苯基)乙酮
• 英文名称: 2-bromo-1-(4-pentylphenyl)ethan-1-one
• 英文别名: ω-Brom-p-(n-pentyl)-acetophenon；2-bromo-1-(4-pentylphenyl)ethanone；2-bromo-4'-n-pentylacetophenone
• CAS: 64328-68-3
• 化学式: C₁₃H₁₇BrO
• mdl: MFCD00218837
• 分子量: 269.181
• InChiKey: AVYNDJWQMUOSJZ-UHFFFAOYSA-N

物化性质

• 熔点：
  <30°C

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2914700090
• 安全说明：
  S26,S37/39

SDS

Name:	2-Bromo-1-(4-pentylphenyl)ethan-1-one 95+% Material Safety Data Sheet
Synonym:	4-n-Pentylphenacylbromid
CAS:	64328-68-3

Section 1 - Chemical Product MSDS Name:2-Bromo-1-(4-pentylphenyl)ethan-1-one 95+% Material Safety Data Sheet
Synonym:4-n-Pentylphenacylbromid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
64328-68-3	2-Bromo-1-(4-pentylphenyl)ethan-1-one	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 64328-68-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H17BrO
Molecular Weight: 269

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 64328-68-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-1-(4-pentylphenyl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 64328-68-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 64328-68-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 64328-68-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-1-(4-戊苯基)乙酮 在 manganese(IV) oxide 、 sodium formate 、 对甲苯磺酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 41.0h， 生成 (E)-ethyl 4-oxo-3-(4-pentylphenyl)but-2-enoate
  参考文献：
  名称：

  一种新的手性C1对称NHC催化的除α-芳基取代的α，β-二取代的enals：全功能化的二氢吡喃酮的对映选择性合成。

  摘要：

  通过高活性酰基偶氮中间体成功开发了第一个对映选择性NHC催化的α-芳基取代的α，β-二取代不饱和醛的活化方法。新的C1对称联芳基饱和的咪唑鎓盐具有出色的能力，能够实现以前无法进行的转化，并且可以以高收率和出色的对映选择性有效地合成相应的完全官能化的二氢吡喃酮。

  DOI：

  10.1039/c5cc00118h
• 作为产物：
  描述：

  4-正戊基苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.33h， 生成 2-溴-1-(4-戊苯基)乙酮
  参考文献：
  名称：

  基于2-氨基咪唑支架的抗分枝杆菌生物膜剂的鉴定。

  摘要：

  结核病（TB）仍然是全球性的重大健康问题，因此迫切需要新的治疗方法。病原体结核分枝杆菌驻留在宿主巨噬细胞内并形成生物膜样群落的能力有助于该疾病的持久性和药物耐受性。可以预防或逆转生物膜样表型的化合物有可能与结核病抗生素一起使用，以克服这种耐受性并缩短治疗时间。我们使用耻垢分枝杆菌作为替代生物，报告了两种抑制和分散分枝杆菌生物膜的新的2-氨基咪唑化合物的鉴定，它们与异烟肼和利福平协同作用，可在体外根除预先形成的耻垢分枝杆菌生物膜，对马勒菌无毒，并展示小鼠血浆中的稳定性。

  DOI：

  10.1002/cmdc.201900033

文献信息

• Synthesis and structure–activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis
  作者：Emanuela Pesce、Marta Bellotti、Nara Liessi、Sara Guariento、Gianluca Damonte、Elena Cichero、Andrea Galatini、Annalisa Salis、Ambra Gianotti、Nicoletta Pedemonte、Olga Zegarra-Moran、Paola Fossa、Luis J.V. Galietta、Enrico Millo

  DOI：10.1016/j.ejmech.2015.05.030

  日期：2015.6

  targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide

  囊性纤维化跨膜电导调节剂 (CFTR) 是存在于上皮细胞膜中的氯离子通道。影响CFTR的突变基因导致囊性纤维化（CF），一种多器官严重疾病。最常见的 CF 突变 F508del 会损害 CFTR 蛋白的加工和活性（门控）。其他突变，如 G551D，只会导致门控缺陷。加工和门控缺陷可以分别被称为一般校正剂和增强剂的小分子作为目标。氨基芳基噻唑 (AAT) 代表了一类有趣的化合物，包括具有双重活性的分子，作为校正剂和增强剂。为了改善 AAT 的活性特征，我们现在设计并合成了一个新化合物库，以建立一个初始 SAR，该 SAR 可以提供有关对救援活动有益或有害的化学基团的指示。使用功能测定法在表达 CFBE41o 的 F508del-CFTR 中测试了新化合物作为校正剂和增强剂。双重活性化合物 AAT-如图 4a 所示，当与校正剂 VX-809 组合时，其特征在于提高的功效和显着的协同作用。此外，通过计算方法，已检测到核苷酸结合域
• [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061452A1

  公开（公告）日：2005-07-07

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。
• [EN] PYRROLE DERIVATIVE<br/>[FR] DÉRIVÉ DU PYRROLE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2005123671A1

  公开（公告）日：2005-12-29

  一般式（１）（式中、Ｒ1は、水素原子又はC1-4アルキル基を示し、Ｒ2はC1-10アルキル基、C3-10シクロアルキル基、メチレンジオキシフェニル基、１，２－エチレンジオキシフェニル基、１，３－プロピレンジオキシフェニル基等を示し、Ｒ3及びＲ4は、同一又は相異なって水素原子、ハロゲン原子、C1-6アルキル基又はC1-6アルコキシ基を示し、Ｒ5は水素原子、ハロゲン原子、ニトロ基、アミノ基、ヒドロキシ基、C1-6アルキル基、C1-6アルコキシ基等を示す。）で表されるピロール誘導体又はその製薬学的に許容される塩であり、免疫担当細胞の異常な活性化に関与するLckの酵素活性を阻害し、臓器移植時の拒絶反応やアトピー性皮膚炎・喘息などの免疫・アレルギー疾患に対して有用な化合物である。

  这是一种用于治疗免疫和过敏疾病的化合物，它是由一般式（１）表示的吡咯衍生物或其制药学上可接受的盐组成，该化合物通过抑制Lck酶活性，从而干预免疫细胞的异常活化，对器官移植时的排斥反应、特应性皮炎和哮喘等免疫和过敏疾病具有益处。
• BENZOIC ACID DERIVATIVES
  申请人：Gillespie Paul

  公开号：US20130079346A1

  公开（公告）日：2013-03-28

  There are disclosed are compounds of the formula: wherein R1 and R2 are as disclosed herein, which are eIF4E inhibitors useful in the treatment of cancers. Also disclosed are compositions comprising the compounds, as well as methods of treating cancer using the compounds.

  已披露的化合物的公式如下：其中R1和R2如本文所述，它们是eIF4E抑制剂，可用于治疗癌症。还披露了包含这些化合物的组合物，以及使用这些化合物治疗癌症的方法。
• Selective synthesis of oxazoles and pyrazines from <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold">α</mml:mi></mml:mrow></mml:math>-bromo-1-phenylethanone using a by-product-promoted strategy
  作者：Changhui Liu、Jiateng Zhao、Yu Qiao、Wenbo Huang、Zhonghao Rao、Yanlong Gu

  DOI：10.1016/j.tet.2018.10.071

  日期：2018.12

  Oxazoles and pyrazines are fundamental heterocycles that widely found in natural products or drugs. In this work, a selective strategy for oxazoles and pyrazines synthesis using α-bromo-1-phenylethanone and ammonium acetate as starting materials was reported. This methodology features mild reaction conditions, readily accessible starting materials and good chemoselectivity. Mechanistic study indicates

  恶唑和吡嗪是在天然产物或药物中广泛发现的基本杂环。在这项工作中，报道了一种以α-溴-1-苯基乙酮和乙酸铵为起始原料合成恶唑和吡嗪的选择性策略。该方法的特点是反应条件温和，原料易得，化学选择性好。机理研究表明，该反应涉及形成恶唑的副产物促进（BPP）过程，即反应过程中原位形成的溴化氢（HBr）促进了整个串联过程。